Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

2.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

3.

Case report: an identical twin with Sertoli-Leydig cell tumor.

Cho K, Havelock JC, Gilks B, Dunne C.

Gynecol Endocrinol. 2018 Jul;34(7):563-566. doi: 10.1080/09513590.2018.1431215. Epub 2018 Jan 24.

PMID:
29366348
4.

Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis.

Grosset AA, Loayza-Vega K, Adam-Granger É, Birlea M, Gilks B, Nguyen B, Soucy G, Tran-Thanh D, Albadine R, Trudel D.

Appl Immunohistochem Mol Morphol. 2017 Dec 21. doi: 10.1097/PAI.0000000000000626. [Epub ahead of print]

PMID:
29271792
5.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

6.

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.

Hoang LN, Gilks BC.

Adv Anat Pathol. 2018 Mar;25(2):85-95. doi: 10.1097/PAP.0000000000000177.

PMID:
28914618
7.

Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers.

Leung AC, Cook LS, Swenerton K, Gilks B, Gallagher RP, Magliocco A, Steed H, Köbel M, Nation J, Brooks-Wilson A, Le ND.

Cancer Epidemiol. 2016 Dec;45:119-125. doi: 10.1016/j.canep.2016.10.010. Epub 2016 Oct 27.

PMID:
27810483
8.

Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC).

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN.

Gynecol Oncol. 2016 Apr;141(1):148-54. doi: 10.1016/j.ygyno.2016.02.002. Epub 2016 Feb 5.

PMID:
26854651
9.

A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomy.

Metcalfe MJ, Afshar K, So AI, Jones EC, Gilks BC, Black PC.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):337-42. doi: 10.5489/cuaj.2796.

10.

Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.

Cheung CC, Garratt J, Won J, Cutz JC, Gilks BC, Tsao M, Torlakovic EE.

Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):677-81. doi: 10.1097/PAI.0000000000000267.

PMID:
26551338
11.

The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.

Wang Y, Chen J, Yang W, Mo F, Senz J, Yap D, Anglesio MS, Gilks B, Morin GB, Huntsman DG.

Neoplasia. 2015 Aug;17(8):650-60. doi: 10.1016/j.neo.2015.08.003.

12.

HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer.

Mondal S, Roy D, Camacho-Pereira J, Khurana A, Chini E, Yang L, Baddour J, Stilles K, Padmabandu S, Leung S, Kalloger S, Gilks B, Lowe V, Dierks T, Hammond E, Dredge K, Nagrath D, Shridhar V.

Oncotarget. 2015 Oct 20;6(32):33705-19. doi: 10.18632/oncotarget.5605.

13.

Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.

Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, Lau S, Gien LT, Gilks B, Clarke B, Cameron A, Nelson G, Han G, Samouëlian V, Ho TC, Louie K, Bernardini MQ.

Gynecol Oncol. 2015 Nov;139(2):268-74. doi: 10.1016/j.ygyno.2015.09.001. Epub 2015 Sep 6.

PMID:
26352641
14.

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.

15.

Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.

Han G, Soslow RA, Wethington S, Levine DA, Bogomolniy F, Clement PB, Köbel M, Gilks B, DeLair D.

Int J Gynecol Pathol. 2015 Jul;34(4):323-33. doi: 10.1097/PGP.0000000000000162.

PMID:
25851704
16.

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.

Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG.

J Pathol. 2015 Jun;236(2):201-9. doi: 10.1002/path.4516. Epub 2015 Mar 23.

PMID:
25692284
17.

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D.

BMC Cancer. 2014 Dec 18;14:982. doi: 10.1186/1471-2407-14-982.

18.

Loss of the Notch effector RBPJ promotes tumorigenesis.

Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A.

J Exp Med. 2015 Jan 12;212(1):37-52. doi: 10.1084/jem.20121192. Epub 2014 Dec 15.

19.

Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee.

Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18. doi: 10.1097/PAI.0000000000000163. Review.

PMID:
25474126
20.

Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel.

Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M; International Ad Hoc Expert Panel.

Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):241-52. doi: 10.1097/PAI.0000000000000069.

21.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

22.

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP.

J Pathol. 2013 Sep;231(1):21-34. doi: 10.1002/path.4230.

23.

Examining the use of salpingectomy with hysterectomy in Canada.

Sandoval C, Fung-Kee-Fung M, Gilks B, Murphy KJ, Rahal R, Bryant H.

Curr Oncol. 2013 Jun;20(3):173-5. doi: 10.3747/co.20.1560. No abstract available.

24.

Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma.

Lim D, Alvarez T, Nucci MR, Gilks B, Longacre T, Soslow RA, Oliva E.

Am J Surg Pathol. 2013 May;37(5):650-8. doi: 10.1097/PAS.0b013e3182851162.

PMID:
23552382
25.

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

Hanna W, Barnes P, Berendt R, Chang M, Magliocco A, Mulligan AM, Rees H, Miller N, Elavathil L, Gilks B, Pettigrew N, Pilavdzic D, Sengupta S.

Curr Oncol. 2012 Dec;19(6):315-23. doi: 10.3747/co.19.1173.

26.

Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement.

D'Angelo E, Ali RH, Espinosa I, Lee CH, Huntsman DG, Gilks B, Prat J.

Am J Surg Pathol. 2013 Apr;37(4):514-21. doi: 10.1097/PAS.0b013e318272c612.

PMID:
23211293
27.

Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases.

Lim D, Wang WL, Lee CH, Dodge T, Gilks B, Oliva E.

Gynecol Oncol. 2013 Feb;128(2):322-6. doi: 10.1016/j.ygyno.2012.11.009. Epub 2012 Nov 13.

PMID:
23153591
28.

New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening.

Chan A, Gilks B, Kwon J, Tinker AV.

Obstet Gynecol. 2012 Oct;120(4):935-40.

PMID:
22996112
29.

Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.

Mohammad T, Garratt J, Torlakovic E, Gilks B, Churg A.

Am J Surg Pathol. 2012 Oct;36(10):1503-8. doi: 10.1097/PAS.0b013e31825d5371.

PMID:
22982894
30.

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.

Hoskins PJ, Le N, Gilks B, Tinker A, Santos J, Wong F, Swenerton KD.

J Clin Oncol. 2012 May 10;30(14):1656-62. doi: 10.1200/JCO.2011.40.1646. Epub 2012 Apr 9.

PMID:
22493415
31.

Beta-catenin expression is prognostic of improved non-small cell lung cancer survival.

Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ, Gilks B, Laskin J, Wiseman SM.

Am J Surg. 2012 May;203(5):654-9. doi: 10.1016/j.amjsurg.2012.01.002. Epub 2012 Mar 7.

PMID:
22402266
32.

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG.

N Engl J Med. 2012 Jan 19;366(3):234-42. doi: 10.1056/NEJMoa1102903. Epub 2011 Dec 21.

33.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

PMID:
21862407
34.

The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience.

Cheung CC, Neufeld H, Lining LA, Pilavdzic D, Copete M, Garratt J, Gilks B, Torlakovic EE.

Am J Clin Pathol. 2011 Jul;136(1):67-73. doi: 10.1309/AJCPQ6I9GHJMCBEV.

PMID:
21685033
35.

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG.

J Pathol. 2011 Jul;224(3):328-33. doi: 10.1002/path.2911. Epub 2011 May 18.

PMID:
21590771
36.

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H.

Breast Cancer Res Treat. 2012 Feb;132(1):131-42. doi: 10.1007/s10549-011-1529-8. Epub 2011 May 15.

PMID:
21574055
37.

Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience.

Copete M, Garratt J, Gilks B, Pilavdzic D, Berendt R, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE.

J Clin Pathol. 2011 Mar;64(3):220-5. doi: 10.1136/jcp.2010.085258. Epub 2011 Jan 22.

PMID:
21258091
38.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

39.

HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.

Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM.

Ann Surg. 2010 Jun;251(6):1107-16. doi: 10.1097/SLA.0b013e3181dbb77e.

PMID:
20485140
40.

Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.

Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT.

Clin Cancer Res. 2010 May 15;16(10):2852-60. doi: 10.1158/1078-0432.CCR-09-2502. Epub 2010 May 11.

41.

Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.

Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee, Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordonez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M, Butany J.

Am J Clin Pathol. 2010 Mar;133(3):354-65. doi: 10.1309/AJCPDYZ1XMF4HJWK.

PMID:
20154273
42.

Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.

Maines-Bandiera S, Woo MM, Borugian M, Molday LL, Hii T, Gilks B, Leung PC, Molday RS, Auersperg N.

Int J Gynecol Cancer. 2010 Jan;20(1):16-22. doi: 10.1111/IGC.0b013e3181bcc96d.

PMID:
20130498
43.

Evolutionary concepts in biobanking - the BC BioLibrary.

Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM.

J Transl Med. 2009 Nov 12;7:95. doi: 10.1186/1479-5876-7-95.

44.

Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.

Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V.

Cancer Res. 2009 Jun 1;69(11):4843-50. doi: 10.1158/0008-5472.CAN-08-3065.

45.

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S.

BMC Cancer. 2009 May 29;9:165. doi: 10.1186/1471-2407-9-165.

46.

The fallopian tube: primary site of most pelvic high-grade serous carcinomas.

Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D.

Int J Gynecol Cancer. 2009 Jan;19(1):58-64. doi: 10.1111/IGC.0b013e318199009c. Review.

PMID:
19258943
47.

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K.

J Clin Oncol. 2008 Dec 10;26(35):5697-704. doi: 10.1200/JCO.2007.15.8659. Epub 2008 Nov 10.

PMID:
19001334
48.

Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.

Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D.

Gynecol Oncol. 2008 Sep;110(3):408-17. doi: 10.1016/j.ygyno.2008.05.010. Epub 2008 Jul 1.

PMID:
18597838
49.

Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?

Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S.

Virchows Arch. 2008 Jun;452(6):589-98. doi: 10.1007/s00428-008-0609-6. Epub 2008 Apr 24. Review.

PMID:
18437416
50.

Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.

Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ.

Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9.

PMID:
17709725

Supplemental Content

Support Center